Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris (Nasdaq: PHVS) recently presented data on their oral bradykinin B2 receptor antagonist, deucrictibant, at several congresses. The data from the Phase 2 RAPIDe-1 study showed that a single dose of deucrictibant resolved symptoms of hereditary angioedema (HAE) attacks in 78.6% of participants within 24 hours, compared to 22.4% for placebo. The Phase 2 CHAPTER-1 study found that treatment satisfaction with deucrictibant was higher than placebo and on par with high-efficacy injectable treatments. Pharvaris expects to publish more data from ongoing open-label extensions to further validate the long-term safety and efficacy of deucrictibant. The company aims to position deucrictibant as a best-in-class treatment for HAE and is exploring additional indications and pipeline expansions.
Pharvaris, a late-stage biopharmaceutical company, will present clinical and nonclinical data at three upcoming congresses focusing on their oral bradykinin B2 receptor antagonists for hereditary angioedema (HAE) attacks. The abstracts will cover topics like pharmacological profiles, relief of attack symptoms, efficacy, and safety of their treatments. The company aims to showcase their developments in the field and highlight the positive outcomes of their trials.
Pharvaris, a late-stage biopharmaceutical company with the stock symbol PHVS, reported strong financials with €368 million in cash, executing pivotal Phase 3 studies for HAE treatment, and preparing for commercial launch. The company's loss for Q1 2024 was €28.0 million, with R&D expenses at €18.5 million and G&A expenses at €9.8 million.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.